{
    "relation": [
        [
            "Arms",
            "Experimental: Arm A (age >= 18, high-dose ipilimumab) Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (closed accrual as of 4/4/14) (adult accrual has completed to Arms A, B, and C as of 8/15/2014)",
            "Experimental: Arm B (age >= 18, recombinant interferon alfa-2b) Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity. (adult accrual has completed to Arms A, B, and C as of 8/15/2014)",
            "Experimental: Arm C (age >= 18, low-dose ipilimumab) Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (adult accrual has completed to Arms A, B, and C as of 8/15/2014)",
            "Experimental: Arm D (age 12-17, high-dose ipilimumab) Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity.",
            "Experimental: Arm E (ages 12-17, recombinant interferon alfa-2b) Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity. (ages 12-17)",
            "Experimental: Arm F (ages 12-17, low-dose ipilimumab) Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (ages 12-17)"
        ],
        [
            "Assigned Interventions",
            "Biological: Ipilimumab Given IV Other Names: Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody BMS-734016 IPILIMUMAB MDX-010 MDX-CTLA4 Yervoy Other: Quality-of-Life Assessment Ancillary studies Other Name: Quality of Life Assessment",
            "Other: Quality-of-Life Assessment Ancillary studies Other Name: Quality of Life Assessment Biological: Recombinant Interferon Alfa-2b Given IV and SC Other Names: Alfatronol Glucoferon Heberon Alfa IFN alpha-2B Interferon alfa 2b INTERFERON ALFA-2B Interferon Alpha-2b Intron A recombinant interferon alfa-2b Sch 30500 Urifron Viraferon",
            "Biological: Ipilimumab Given IV Other Names: Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody BMS-734016 IPILIMUMAB MDX-010 MDX-CTLA4 Yervoy Other: Quality-of-Life Assessment Ancillary studies Other Name: Quality of Life Assessment",
            "Biological: Ipilimumab Given IV Other Names: Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody BMS-734016 IPILIMUMAB MDX-010 MDX-CTLA4 Yervoy",
            "Biological: Recombinant Interferon Alfa-2b Given IV and SC Other Names: Alfatronol Glucoferon Heberon Alfa IFN alpha-2B Interferon alfa 2b INTERFERON ALFA-2B Interferon Alpha-2b Intron A recombinant interferon alfa-2b Sch 30500 Urifron Viraferon",
            "Biological: Ipilimumab Given IV Other Names: Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody BMS-734016 IPILIMUMAB MDX-010 MDX-CTLA4 Yervoy"
        ]
    ],
    "pageTitle": "Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery - Full Text View - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/NCT01274338?recr=Open&cond=%22Melanoma%22&rank=17",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 3,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990445.44/warc/CC-MAIN-20150728002310-00138-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 859236979,
    "recordOffset": 859221568,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{25376=Patients must have primary cutaneous melanoma that belong to one of the following American Joint Commission on Cancer (AJCC) stages (2009 AJCC Melanoma Staging System):}",
    "textBeforeTable": "May 2018 (Final data collection date for primary outcome measure) Estimated Primary Completion Date: May 2011 Study Start Date: 1545 Estimated Enrollment: Incidence of toxicity assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 70 days after completion of study treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0] Will be summarized by treatment group and NCI CTCAE worst grade. Toxicity incidence rate and 95% confidence interval for each type will be presented. The percentages of patients experiencing the worst degree toxicities (highest grade event per adverse event [AE] type per patient) will be evaluated and the distribution of the worst degree toxicities will be compared among the treatment arms. The proportion of patients with worst degree toxicities with 3 or higher will be summarized and compared among the treatment arms. Chi-square test will be used for AE comparisons. The two-sample t-test will be used to compare continuous measurements and Chi-square test will be used to compare the categorical outcomes between the two treatment groups. Longitudinal regression models will also be used to address the overall change over",
    "textAfterTable": "\u00a0 Show Detailed Description \u00a0 Eligibility Ages Eligible for Study: \u00a0 12 Years and older Genders Eligible for Study: \u00a0 Both Accepts Healthy Volunteers: \u00a0 No Criteria Inclusion Criteria: All patients must have disease-free status documented by a complete physical examination and imaging studies within 4 weeks prior to randomization; imaging studies must include a total body positron emission tomography (PET)-computed tomography (CT) scan (with or without brain) and brain magnetic resonance imaging (MRI) or CT (if MRI is contraindicated); if PET-CT cannot be done, CT of neck, chest, abdomen, and pelvis should be done If for some reason a CT cannot be done, an MRI may be done instead; any other imaging studies if performed (eg, bone scan) must show no evidence of disease Patients must have primary cutaneous melanoma that belong to",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}